Erkut H. Borazanci

Oncology

9003 E Shea Blvd
Scottsdale, AZ 85260

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform.

Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform.

Journal: Oncoimmunology

Published: July 06, 2026

Reply to "Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer".

Reply to "Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer".

Journal: Cancer

Published: May 16, 2026

A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer.

A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer.

Journal: The oncologist

Published: March 02, 2026

Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma.

Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma.

Journal: Current oncology (Toronto, Ont.)

Published: October 16, 2025

Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer.

Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer.

Journal: Redox biology

Published: October 09, 2025

A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer.

A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer.

Journal: Cancer

Published: September 10, 2025

Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer.

Phase II Trial of Vemurafenib and Sorafenib Combination in Advanced KRAS-Mutated Metastatic Pancreatic Cancer.

Journal: Journal of immunotherapy and precision oncology

Published: August 11, 2025

Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma.

Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma.

Journal: Gastroenterology

Published: June 24, 2025

Cross-platform comparison of gene expression-based cancer molecular subtyping reveals discrepancies with exome capture methods.

Cross-platform comparison of gene expression-based cancer molecular subtyping reveals discrepancies with exome capture methods.

Journal: NPJ precision oncology

Published: April 30, 2025

Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma.

Exosomal ALPPL2 and THBS2 as biomarkers for early detection and disease monitoring of pancreatic ductal adenocarcinoma.

Journal: British journal of cancer

Published: March 10, 2025

Adult pancreatoblastoma: Systematic review of the literature and case report of a young adult patient.

Adult pancreatoblastoma: Systematic review of the literature and case report of a young adult patient.

Journal: World journal of gastrointestinal oncology

Published: March 05, 2025

Skin microbiome differences in pancreatic adenocarcinoma, other cancers, and healthy controls: a pilot study.

Skin microbiome differences in pancreatic adenocarcinoma, other cancers, and healthy controls: a pilot study.

Journal: Frontiers in oncology

Published: September 12, 2024

Showing 1-12 of 58

Last Updated: 09/26/2026